Article

Lab Invest 2003, 83:1267–1277

Renal Damage in the SHR/N-cp Type 2 Diabetes Model: Comparison of an Angiotensin-Converting Enzyme Inhibitor and Endothelin Receptor Blocker

Marie-Luise Gross1, Eberhard Ritz2, Arne Schoof1, Burkhard Helmke1, Amy Parkman3, Orien Tulp4, Klaus Münter5 and Kerstin Amann6

  1. 1Department of Pathology, Univeristy of Heidelberg, Heidelberg, Germany
  2. 2Department of Internal Medicine, Univeristy of Heidelberg, Heidelberg, Germany
  3. 3Department of Bioscience and Biotechnology, Drexel University Philadelphia, Pennsylvania
  4. 4London College of Medicine, Technology and Research, London, United Kingdom
  5. 5Bayer AG, Wuppertal, Germany
  6. 6Department of Pathology, University of Erlangen, Erlangen, Germany

Correspondence: Dr. Marie-Luise Gross, Department of Pathology, University of Heidelberg, Im Neuenheimer Feld 220/221, 69120 Heidelberg, Germany. E-mail: Marie-Luise_Gross@med.uni-heidelberg.de

Received 24 January 2003.

Top

Abstract

The pathomechanisms that cause renal damage in diabetes have not been completely clarified. Treatment with angiotensin-converting enzyme inhibitors (ACE-i) is highly effective but fails to completely prevent end-stage renal disease. The effects of ETA-receptor blockers (ETA-RB) on renal damage are controversial and have rarely been investigated in type 2 diabetes. We compared the influence of the selective ETA-RB LU135252 and the ACE-i Trandolapril on renal structure in the SHR/N-cp rat model of type 2 diabetes. Three-month-old male SHR/N-cp rats were left untreated or received daily either Trandolapril or LU135252. The experiment was terminated after 6 months. The glomerulosclerosis index; tubulointerstitial damage index; and glomerular geometry, glomerular cell number, and capillary density were investigated. Proliferating cell nuclear antigen and desmin expression of podocytes, renal mRNA expression of endothelin (ET-1) and transforming growth factor-beta, blood pressure, and urine albumin excretion were measured. The glomerulosclerosis index was significantly higher in untreated diabetic animals than in the groups that were treated with ACE-i and ETA-RB. There were analogous changes in tubulointerstitial damage index. Treatment with either substance comparably lowered urinary albumin excretion in diabetic SHR/N-cp. Podocyte and endothelial cell numbers per glomerulus decreased in untreated diabetic animals; this was prevented by the ACE-i but not by the ETA-RB. Glomerular capillary length density was lower in SHR/N-cp, and this was normalized by ACE-i only. Increased expression of desmin and proliferating cell nuclear antigen expression of podocytes in the SHR/N-cp was abrogated by ACE-i but not by ETA-RB. Treatment with ACE-i or ETA-receptor antagonist resulted in less structural and functional alterations, but the ETA-RB was inferior to the ACE-i. This is particularly the case for podocyte changes pointing to angiotensin II–dependent pathomechanisms.

Extra navigation

.

naturejobs

ADVERTISEMENT